Status epilepticus associated with the combination of valproic acid and clomipramine

Therapeutic Drug Monitoring

Volumn 19, Issue 1, 1997, Pages 71-73

  DeToledo, John C ^a   Haddad, H ^b   Ramsay, R E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Fairview Hosp Train Cent   (United States)

Author keywords

Chlorimipramine; Metabolism; Seizures; Status epilepticus; Valproic acid

Indexed keywords

CLOMIPRAMINE; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DISEASE ASSOCIATION; DRUG ELIMINATION; ENZYME INHIBITION; EPILEPTIC STATE; FEMALE; GENETIC PREDISPOSITION; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SEIZURE;

ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLOMIPRAMINE; DEPRESSIVE DISORDER; FEMALE; HUMANS; SEIZURES; STATUS EPILEPTICUS; VALPROIC ACID;

EID: 0031427878     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199702000-00012     Document Type: Article

References (15)

1. Betts TA. Depression, anxiety and epilepsy. In: Reynolds EH, Trimble MR, eds. Epilepsy and psychiatry. Edinburgh, Churchill Livingstone, 1981:60-72.
2. Nielsen KK, Brosen K, Hansen MGJ, Gram LF. Single dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994;55:518-27.
3. Balant-Gorgia AE, Balant LP, Zysset T. High plasma concentrations of desmethylchlorimipramine after chronic administration of clomipramine to a poor metabolizer. Eur J Clin Pharmacol 1987; 32:101-2.
4. Leyberg JT, Denmark JC. The treatment of depressive states with imiprimine hydrochloride (Tofranil). J Ment Sci 1959;105:1123.
5. Killoh LG, Davison K, Osselton JW. An electroencephalographic study of the analeptic effects of imipramine. Electroencephalogr Clin Neurophysiol 1961;13:216.
6. Betts TA, Kalra PL, Cooper R, Jeavons PM. Epileptic fits as a probable side effect of amitryptyline. Lancet 1968;1:390-3.
7. Escande M, Gayral L, Goldberger E, Jarrige A, Kulik J. Accidents convulsifs et modifications EEG au cours des traitements par les antidepresseurs tricycliques. L'Encephale 1976;II:133-51.
8. Koella WP, Glatt A, Klebs K, Durst T. Epileptic phenomena induced in the cat by the antidepressants maprotiline, imipramine, clomipramine and amitryptiline. Biol Psychiatry 1979;14:485-97.
9. McTavish D, Benfield P. Clomiprimine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990;39: 136-53.
10. Bertschy G, Vandel S, Jounet JM, Allers G. Interaction valpromide-amytriptyline. Augmentation de la biodisponibilite de l'amytriptyline et de la nortriptyline par la valpromide. L'Encephale 1990;16:43-5.
11. Kapetanovic I, Kupfberg H, Porter R, Theodore W, Schulman E, Penry JK. Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther 1981;29:480-6.
12. Wang SL, Lai ML, Huang JD. Increased microsomal irreversible binding of phenytoin by valproic acid. Biochem Pharmacol 1991; 42:1143-4.
13. Robbins RO, Wedlund PJ, Kuhn R, Baumann RJ, Levy RH, Chang SL. Inhibition of epoxide hydrolase by valproic acid in epileptic patients taking carbamazepine. Br J Clin Pharmacol 1990;29:759-62.
14. Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet 1991;20:447-62.
15. Balant-Gorgia AE, Gay M, Gex-Fabry M, Balant LP. Persistent impairment of clomipramine demethylation in recently detoxified alcoholic patients. Ther Drug Monit 1992;14:119-24.